Viking Therapeutics, Inc (VKTX) Stock Price
VKTXStock
$25.17−27.53%52W
Market Cap$3.20B
P/E—
PEG Ratio—
Div yield—
Beta0.71
VKTX Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-39.04%
Price vs S&P 500 (4W)-15.08%
VGM Score39.70
VKTX Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$1.21 | -$1.10 | +8.85%(+$0.11) | |
| Q1 2026 | -$0.91 | -$1.37 | -50.51%(-$0.46) | |
| Q4 2025 | -$0.90 | -$1.38 | -53.10%(-$0.48) | |
| Q3 2025 | -$0.67 | -$0.81 | -20.07%(-$0.14) | |
| Q2 2025 | -$0.44 | -$0.58 | -31.61%(-$0.14) |
VKTX Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.23
4.23
4.23
4.23
Industry Peers — Pharmaceuticals(574)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
VKTXViking Therapeutics, Inc | — | — | D | — | — | — | — | $25.17 |
| LLYEli Lilly & Co. | D | B | A | 14.9x | 49.6% | 83.4% | 27.6% | $1257.03 |
| JNJJohnson & Johnson | D | C | B | 6.2x | 7.8% | 67.7% | 14.9% | $255.56 |
| ABBVABBVIE INC. | D | C | A | 7.8x | 10.4% | 72.8% | -2.9% | $285.42 |
| MRKMerck & Co., Inc. | D | C | A | 5.4x | 4.6% | 77.3% | 21.2% | $145.95 |
| NVSNovartis AG | C | C | B | 4.9x | 3.3% | 75.0% | 15.3% | $150.62 |
| AZNAstraZeneca PLC | C | B | B | 4.3x | 8.6% | 81.3% | 21.9% | $165.41 |
| ABTAbbott Laboratories | C | C | B | 3.9x | 8.1% | 56.8% | 8.2% | $104.89 |
| NVONovo-Nordisk A/S | B | C | C | 3.5x | 5.6% | 80.7% | 20.7% | $38.83 |
| PFEPfizer Inc. | C | D | A | 2.6x | -0.2% | 74.7% | -3.5% | $29.58 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | 10.1x | 10.2% | 86.0% | 8.3% | $499.74 |
About Viking Therapeutics, Inc
Viking Therapeutics is a biopharmaceutical company developing treatments for metabolic and endocrine disorders. Its clinical pipeline includes VK2809 and VK0214, oral selective thyroid hormone receptor beta agonists, and VK5211, an oral selective androgen receptor modulator, each targeting unmet medical needs in hormonal conditions.